Olema Oncology
Angelos Dovletoglou is an accomplished leader in the pharmaceutical industry, currently serving as Senior Vice President of CMC and Supply Chain at Olema Oncology since 2025, overseeing planning and execution of CMC Development, Manufacturing, and Supply Chain activities. Previous roles include Senior Vice President of Technical Operations at Repare Therapeutics and Origin Biosciences, where successful development and delivery of clinical candidates were achieved. Dovletoglou has held significant positions at Epizyme, Biogen, Momenta Pharma, and Merck Research Laboratories, contributing to regulatory submissions and commercial launches across multiple programs. The academic background includes a Ph.D. in Inorganic Chemistry from the University of North Carolina at Chapel Hill and a BS in Chemistry from Ethnikon kai Kapodistriakon Panepistimion Athinon.
This person is not in any teams
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.